Progentos Therapeutics

Pioneering a treatment for multiple sclerosis that harnesses the body's innate ability to heal.

Founded 2023 Series A Total: $65.00M

Progentos Therapeutics is a pioneering startup that is dedicated to developing a treatment for multiple sclerosis, focused on harnessing the body's innate ability to heal. The company's approach involves stimulating the body's natural repair mechanisms, aiming to provide a breakthrough in the treatment of this debilitating condition. Established in 2023, Progentos Therapeutics has already secured a significant $65.00M Series A investment on 20 May 2024. The funding comes from a group of prominent investors including Longwood Fund, Alta Partners, Forbion, Dolby Ventures, and Mission BioCapital. This backing not only highlights the potential of Progentos Therapeutics but also demonstrates the confidence that leading investors have in the startup's vision and capabilities. With its innovative approach and strong financial support, Progentos Therapeutics is poised to make a significant impact in the field of multiple sclerosis treatment and has the potential to bring about positive change for patients and the healthcare industry as a whole.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	••••••	5		20 May 2024

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

••••••

20 May 2024

FAQ About Progentos Therapeutics

Pioneering a treatment for multiple sclerosis that harnesses the body's innate ability to heal.

Progentos Therapeutics was founded in 2023.

Progentos Therapeutics has completed 1 funding round, raising a total of $65.00M. The latest funding stage is Series A.

General Information

Track Progentos Therapeutics

About Progentos Therapeutics

Funding Rounds & Investors (1)

FAQ About Progentos Therapeutics

Don't just browse. Track.